新型非典型抗精神病药:依匹哌唑

A novel atypical antipsychotic drug:brexpiprazole

依匹哌唑为一新型非典型抗精神病药,2015年7月10日由美国食品和药物管理局批准上市,用于精神分裂症与抑郁障碍的辅助治疗。依匹哌唑的作用机制尚未完全清楚,其治疗精神分裂症或抑郁症的机制可能通过对5-HT_(1A)和多巴胺D_2受体的部分激动作用和对5-HT_(2A)受体的拮抗作用起效。依匹哌唑常见的不良反应有体重增加和静坐不能。临床研究表明,依匹哌唑对精神分裂症与抑郁障碍的辅助治疗有效且安全性和耐受性好。本文对依匹哌唑的药理学、药动学、临床评价和安全性等进行介绍。

Brexpiprazole is a novel atypical antipsychotic drug. The drug was approved by the U.S. FDA on July 10, 2015 for the treatment of schizophrenia and as an adjunctive treatment for depression. The mechanism of the effect of brexpiprazole is not fully understood, and it may be through a combination of partial agonistic activity at 5- HTIA and dopamine D2 receptors and antagonistic activity at 5- HT2A receptors. The most common adverse reactions of brexpiprazole are akathisia and weight increase. Clinical studies indicated that brexpiprazole was effective in the treatment of schizophrenia and major depressive disorder, and it had a good safety and tolerability profile. The pharmacology, pharmacokinetics, clinical evaluation and safety of brexpiprazole were reviewed in this paper.